Phase 2
Completed N=308
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
Prophylaxis · Stem Cell Transplant Complications
Source: ClinicalTrials.gov NCT03850379 ↗
Enrolled (actual)
308
Serious AEs
14.0%
Results posted
Oct 2025
Primary outcomePrimary: Proportion of Bloodstream Bacterial Infections — 18; 18 participants
Summary
Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agent in some transplant centers. In some small retrospective studies ciprofloxacin prophylaxis was associated with a higher rate of breakthrough gram positive bloodstream infections. However, the optimum oral agent for antibacterial prophylaxis in transplant recipients remains uncertain.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Bloodstream Bacterial Infections |
18; 18 | — |
Eligibility Criteria
Inclusion Criteria
- Patients 18-75 years of age with a diagnosis of a hematological malignancy. Meet the stem cell transplant program criteria to undergo autologous or allogeneic hematopoietic stem cell transplantation.
Exclusion Criteria
- Prolonged QT
- Allergies to ciprofloxacin or levofloxacin
Data sourced from ClinicalTrials.gov (NCT03850379). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.